Donnée clinique de NBTXR3

2020 – ASCO – NBTXR3 With Anti PD1 Therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Despite the past decade of transformative advances in immuno-oncology, the response rate to checkpoint inhibitors (ICIs) remains low (~15%). There is significant interest in developing strategies to overcome resistance to these treatments, thus increasing response rate. Emerging evidence suggests that radiation therapy (RT) could potentially augment the antitumor response to ICIs through synergic effect. […]

Continuer la lecture…

2020 – MHNCS – NBTXR3 for locally advanced HNSCC

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Elderly and/or frail patients (pts) with head and neck squamous cell carcinoma (HSNCC) remain a challenging to manage and neglected population regarding clinical trials and data generation to support treatment choices. Despite representing 20% of the HNSCC population no consensus exists on what is the optimal treatment for these pts with locally advanced (LA) disease, vulnerable to treatment-induced toxicities with the current standard of care. […]

Continuer la lecture…

2020 – ASCO-SITC – NBTXR3 with anti-PD-1 therapy

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Most cancer patients present resistance to immune therapy; only approximately 15% of patients respond to immune checkpoint inhibitors (ICI). Strategies able to increase ICI response are thus of great interest. Radiotherapy (RT), by acting as an immunomodulator is a good candidate to increase the proportion of ICI responders. However, RT dose and ultimate efficacy are limited by potential toxicity to healthy tissues. NBTXR3, a first in class radioenhancer administered by intratumoral injection, has been designed at the nanoscale to increase RT energy dose deposition within the tumor. […]

Continuer la lecture…

2020 – ASCO GI – Treatment of liver cancers with NBTXR3

Abstracts, Donnée clinique de NBTXR3, Foie

Treatment of unresectable liver cancer or liver metastases (mets) by stereotactic body radiotherapy is well tolerated but limited by the need to preserve liver function. Increasing energy deposition in the tumor while at the same time maintaining the dose in healthy tissue remains a major challenge in radiation oncology that could be achieved by NBTXR3 (hafnium oxide nanoparticles) when activated by radiotherapy (RT). NBTXR3 augments energy dose deposit within tumor cells, increasing tumor cell death compared to RT alone, while sparing healthy tissues. […]

Continuer la lecture…

2019 – A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated With an Anti-PD-1 Therapy

Abstracts, Donnée clinique de NBTXR3, Abstracts, Donnée clinique de NBTXR3, Foie, Tête & Cou, Foie, Poumon, Poumon, Tête & Cou

The majority of cancer patients are resistant to immune therapy; only around 15% respond to immune checkpoint inhibitors (ICI). Thus, strategies able to increase ICI response are of great interest. Recent work suggests radiotherapy (RT) can act as an immunomodulator to increase the proportion of ICI responders and improve clinical outcomes. […]

Continuer la lecture…

2019 – NBTXR3 for the treatment of locally advanced HNSCC in frail and/or elderly patients: a phase I/II study

Abstracts, Donnée clinique de NBTXR3, Tête & Cou

Elderly head and neck squamous cell carcinoma (HSNCC) patients (pts) ineligible for standard of care treatment require new therapeutic approaches. NBTXR3, hafnium oxide nanoparticles, may represent such an option. NBTXR3 is activated by radiotherapy, enhancing its effects, leading to physical destruction of cancer cells. […]

Continuer la lecture…

2019 – Phase I study of hafnium oxide nanoparticles activated by Intensity Modulated Radiation Therapy (IMRT) as a new therapeutic option for elderly or frail HNSCC patients

Abstracts, Donnée clinique de NBTXR3, NO-RIGHTS, Tête & Cou

New therapeutic approaches are needed for elderly or frail head and neck squamous cell carcinoma (HNSCC) patients (pts) ineligible for standard of care. NBTXR3, hafnium oxide nanoparticles injected intratumorally, may represent an option. Otherwise inert, NBTXR3 augments the radiation therapy (RT) dose within tumor cells when activated by RT, increasing tumor cell death compared to RT alone. […]

Continuer la lecture…

2019 – Phase I/II trial of NBTXR3 activated by SBRT in patients with hepatocellular carcinoma or liver metastasis

Abstracts, Donnée clinique de NBTXR3, Foie

Treatment of hepatocellular carcinoma (HCC) and liver metastasis (mets) is challenging due to presence of underlying disease, e.g. cirrhosis. Stereotactic body radiation therapy (SBRT) is a well-tolerated alternative for inoperable patients (pts), yet maximal dose to the tumor is limited by potential toxicity to surrounding healthy tissues. […]

Continuer la lecture…

2019 – Hafnium oxide nanoparticles activated by SBRT for the treatment of hepatocellular carcinoma and liver metastasis: a phase I/II trial

Abstracts, Donnée clinique de NBTXR3, Foie, NO-RIGHTS

The medical community faces important challenges to treat liver cancer because of underlying disease. Reduction of healthy tissue irradiation while at the same time increasing energy dose deposit within tumor cells still constitutes a challenge in radiation oncology. NBTXR3, hafnium oxide nanoparticles, increase energy deposit inside tumor cells only when activated by ionizing radiation such as stereotactic body radiotherapy (SBRT) and thus increase tumor cell death compared to radiation alone. […]

Continuer la lecture…

2019 – ESMO IO – NBTXR3 with anti-PD-1

Abstracts, Donnée clinique de NBTXR3, Foie, Poumon, Tête & Cou

Continuer la lecture…

Les abstracts de cette section concernent les résultats des essais cliniques menés avec NBTXR3.